[{"orgOrder":0,"company":"Covis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"LUXEMBOURG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Aclidinium Bromide","moa":"||Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Covis Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Covis Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Covis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Aclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.27000000000000002,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Covis Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Aclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.27000000000000002,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"AstraZeneca \/ Covis Pharma","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Covis Pharma"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Niox","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Aclidinium Bromide","moa":"Muscarinic acetylcholine receptor M3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol, Powder","sponsorNew":"AstraZeneca \/ Circassia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Circassia Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Aclidinium Bromide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Duaklir (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled respiratory medicines used for the maintenance treatment of COPD. Eklira is a LAMA and Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2...

                          Product Name : Duaklir

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 25, 2022

                          Lead Product(s) : Aclidinium Bromide,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Under the terms of the Acquisition agreement, Covis Pharma has completed the acquisition of Eklira® (aclidinium bromide), known as Tudorza® in US and marketed as Bretaris® in some countries, and Duaklir® (aclidinium bromide/formoterol), marketed as B...

                          Product Name : Eklira

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 01, 2022

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Covis Pharma

                          Deal Size : $270.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Covis Pharma acquired the rights of Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol), inhaled respiratory medicines used for the maintenance treatment of COPD from AstraZeneca.

                          Product Name : Eklira

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 11, 2021

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Covis Pharma

                          Deal Size : $270.0 million

                          Deal Type : Agreement

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza® and Duaklir® together with certain ancillary rights and assets, from Circassia.

                          Product Name : Eklira

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 04, 2020

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Niox

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 08, 2017

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 08, 2017

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 09, 2017

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Quintiles Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 16, 2017

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Parexel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 13, 2016

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 23, 2015

                          Lead Product(s) : Aclidinium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Menarini

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank